Nurix Therapeutics Presents at Baird Global Healthcare Conference 2025

Nurix Therapeutics presents at Baird Global Healthcare Conference 2025. Brian Skorney, a senior biotech analyst, leads the presentation. Details of the presentation are not specified.

On September 10, 2025, Nurix Therapeutics, Inc. (NASDAQ: NRIX) presented at the Baird Global Healthcare Conference. Brian Skorney, a senior biotech analyst, led the presentation. The company is focused on the discovery, development, and commercialization of targeted protein degradation medicines aimed at improving treatment options for patients with cancer and inflammatory diseases Nurix Therapeutics : investor deck HCW Final^[1].

During the presentation, Arthur Sands, the CEO, President, and Director of Nurix Therapeutics, highlighted the company's strategic priorities. Sands noted that the company is about to enter pivotal studies in chronic lymphocytic leukemia (CLL) as their primary program, which includes the highly selective BTK degrader, NX-5948, now known as bexobrutideg or Bexdeg. The company is actively planning Phase II and III programs for this drug, with recent disclosures on the design considerations for the Phase III study Certain H Shares of Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. are subject to a Lock-Up Agreement Ending on 11-SEP-2025.^[2].

Additionally, Sands mentioned other degraders in the pipeline, such as NX-2127, which targets BTK and transcription factors IKZF1 and IKZF3, and NX-1607, an inhibitor of Casitas B-lineage lymphoma proto-oncogene B (CBL-B). These drugs are in various stages of development, including preclinical and partnered drug discovery pipelines Nurix Therapeutics : investor deck HCW Final^[1].

The presentation underscored Nurix Therapeutics' commitment to advancing innovative therapies and its robust pipeline of targeted protein degradation medicines. The company's strategic focus on CLL and other cancer types positions it as a key player in the biopharmaceutical industry.

The presentation at the Baird Global Healthcare Conference 2025 provided investors and financial professionals with an update on the company's progress and future plans, reinforcing its potential in the biopharmaceutical sector.